Seer, Inc. (NASDAQ:SEER – Get Free Report) CFO David Horn sold 7,309 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $2.03, for a total transaction of $14,837.27. Following the sale, the chief financial officer owned 486,650 shares in the company, valued at $987,899.50. The trade was a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Seer Stock Up 1.5%
SEER stock traded up $0.03 during midday trading on Wednesday, hitting $2.05. The company’s stock had a trading volume of 182,540 shares, compared to its average volume of 632,272. Seer, Inc. has a 12 month low of $1.55 and a 12 month high of $2.41. The company has a 50 day moving average of $1.97 and a two-hundred day moving average of $1.88. The firm has a market capitalization of $112.71 million, a price-to-earnings ratio of -1.68 and a beta of 1.55.
Seer (NASDAQ:SEER – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Seer had a negative return on equity of 27.23% and a negative net margin of 478.05%.The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.55 million.
Institutional Investors Weigh In On Seer
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SEER. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Friday, July 17th. Canaccord Genuity Group initiated coverage on shares of Seer in a research note on Monday, May 4th. They issued a “buy” rating and a $4.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $4.00.
Get Our Latest Analysis on SEER
About Seer
Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.
See Also
- Five stocks we like better than Seer
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
